Loading
A phase 1/2 trial of LUM015 in colorectal cancer, pancreatic ductal adenocarcinoma, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by Lumicell, Inc., now recruiting.
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers is a phase 1/2 interventional study registered as NCT02584244 by Lumicell, Inc., with 66 participants planned, started 2016-08-04 and due to reach its primary completion in 2026-12. Interventions recorded: LUM015 and LUM 2.6 Imaging Device.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/